Plain-English translation of NCT06214572 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding radiation therapy to Gemcitabine-based chemotherapy can help people with advanced gallbladder cancer live longer. Currently, patients with unresectable gallbladder cancer receive 6 months of chemotherapy alone, with a typical survival of 10–12 months. This study will compare chemotherapy by itself versus chemotherapy combined with focused radiation therapy to see which approach works better.
Gallbladder cancer is particularly common in India and most patients are diagnosed when the cancer is already advanced and cannot be removed surgically. Doctors at this cancer center have seen promising early results when radiation is added to chemotherapy, but this has never been formally tested in a large, rigorous trial to confirm whether it truly helps patients live longer.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will first receive 3 months of chemotherapy to see how your cancer responds. If your cancer stays stable or improves, you will then be randomly assigned to one of two groups: either continuing chemotherapy alone for 3 more months, or receiving focused radiation therapy (in 10–15 short sessions over 2–3 weeks) followed by 3 more months of chemotherapy. The study will track your health and survival over time to see which approach works better.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
India